eUpdate – Nasopharyngeal Carcinoma Treatment Recommendations

ESMO–EURACAN Clinical Practice Guideline update for nasopharyngeal carcinoma: adjuvant therapy and first-line treatment for recurrent/metastatic disease

Ann Oncol. 2023;34(3):247-250.
P. Bossi, A. T. Chan , C. Even & J.-P. Machiels, on behalf of the ESMO Guidelines Committee

This update refers to Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. P. Bossi, A.T. Chan, L. Licitra et al. Ann Oncol 2021; 32(4): 452-465.

• This special article provides updated treatment recommendations for nasopharyngeal carcinoma.
• In high-risk locoregionally advanced NPC, the addition of metronomic or standard dose adjuvant capecitabine to CRT improves PFS.
• Camrelizumab or toripalimab added to platinum and gemcitabine improves PFS as first-line metastatic treatment in endemic NPC areas.